AstraZeneca PLC (LON:AZN - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of £114.82 ($144.87) and traded as high as £119.08 ($150.24). AstraZeneca shares last traded at £117.08 ($147.72), with a volume of 2,988,152 shares.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on the company. Berenberg Bank restated a "buy" rating and set a GBX 140 ($1.77) price objective on shares of AstraZeneca in a report on Monday, January 27th. JPMorgan Chase & Co. restated an "overweight" rating and set a £140 ($176.63) price target on shares of AstraZeneca in a research note on Friday, November 22nd. Finally, Shore Capital restated a "buy" rating on shares of AstraZeneca in a report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of GBX 7,542.80 ($95.17).
View Our Latest Report on AstraZeneca
AstraZeneca Price Performance
The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83. The business has a 50-day moving average of £109.07 and a 200 day moving average of £114.70. The firm has a market capitalization of £226.69 billion, a PE ratio of 32.29, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17.
AstraZeneca Company Profile
(
Get Free Report)
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
See Also
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
